Formulation-Driven Optimization of PEG-Lipid Content in Lipid Nanoparticles for Enhanced mRNA Delivery In Vitro and In Vivo
Pharmaceutics · 22.07.2025 · 17 (8) · 950
DOI: 10.3390/pharmaceutics17080950 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 22.07.2025. Verfasst von Wei Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Colloid and Interface Chemistry of the Ministry of Education, School of Chemistry and Chemical Engineering, Shandong University, Ji…. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Taishan Scholars Program of Shandong Province, Fundamental Research Fund of Shandong University.
Abstract (Originalsprache)
Background
Lipid nanoparticles (LNPs) represent one of the most effective non-viral vectors for nucleic acid delivery and have demonstrated clinical success in siRNA therapies and mRNA vaccines. While considerable research has focused on optimizing ionizable lipids and helper lipids, the impact of PEGylated lipid content on LNP-mediated mRNA delivery, especially in terms of in vitro transfection efficiency and in vivo performance, remains insufficiently understood.
Methods
In this study, LNPs were formulated using a self-synthesized ionizable lipid and varying molar ratios of DMG-PEG2000. Nanoparticles were prepared via nanoprecipitation, and their physicochemical properties, mRNA encapsulation efficiency, cellular uptake, and transfection efficiency were evaluated in HeLa and DC2.4 cells. In vivo delivery efficiency and organ distribution were assessed in mice following intravenous administration.
Results
The PEGylated lipid content exerted a significant influence on both the in vitro and in vivo performance of LNPs. A bell-shaped relationship between PEG content and transfection efficiency was observed: 1.5% DMG-PEG2000 yielded optimal mRNA transfection in vitro, while 5% DMG-PEG2000 resulted in the highest transgene expression in vivo. This discrepancy in optimal PEG content may be attributed to the trade-off between cellular uptake and systemic circulation: lower PEG levels enhance cellular internalization, whereas higher PEG levels improve stability and in vivo bioavailability at the expense of cellular entry. Furthermore, varying the PEG-lipid content enabled the partial modulation of organ distribution, offering a formulation-based strategy to influence biodistribution without altering the ionizable lipid structure.
Conclusions
This study highlights the critical role of PEGylated lipid content in balancing nanoparticle stability, cellular uptake, and in vivo delivery performance. Our findings provide valuable mechanistic insights and suggest a straightforward formulation-based strategy to optimize LNP/mRNA systems for therapeutic applications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Colloid and Interface Chemistry of the Ministry of Education, School of Chemistry and Chemical Engineering, Shandong University, Jinan 250100, China.
ORCID-Profile: Wei Liu, Chuanxu Yang
Förderung
- National Natural Science Foundation of China
- Taishan Scholars Program of Shandong Province
- Fundamental Research Fund of Shandong University
Zitieren
APA
Liu, W., Zhang, M., Lv, H., & Yang, C. (2025). Formulation-Driven Optimization of PEG-Lipid Content in Lipid Nanoparticles for Enhanced mRNA Delivery In Vitro and In Vivo. Pharmaceutics, 17(8), 950. https://doi.org/10.3390/pharmaceutics17080950
Vancouver
Liu W, Zhang M, Lv H, Yang C. Formulation-Driven Optimization of PEG-Lipid Content in Lipid Nanoparticles for Enhanced mRNA Delivery In Vitro and In Vivo. Pharmaceutics. 2025;17(8):950. doi:10.3390/pharmaceutics17080950
BibTeX
@article{Liu2025,
author = {Liu, Wei and Zhang, Meihui and Lv, Huiyuan and Yang, Chuanxu},
title = {Formulation-Driven Optimization of PEG-Lipid Content in Lipid Nanoparticles for Enhanced mRNA Delivery In Vitro and In Vivo},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {8},
pages = {950},
doi = {10.3390/pharmaceutics17080950}
}
EUVIMED